Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- Publisher
- LANCET ONCOLOGY
- Language
- 영어
- ISSN
- 1470-2045
- Citation Volume
- 21
- Citation Number
- 3
- Citation Start Page
- 373
- Citation End Page
- 386
- Files in This Item:
-
-
There are no files associated with this item.
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.